Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study Meeting Abstract

  

Authors:	Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; Fleisher, M.; Larson, S. M.; Scher, H. I.
Abstract Title:	Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
Meeting Title:	2012 Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	30
Issue:	5 Suppl.
Meeting Dates:	2012 Feb 2-4
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2012-02-10
Language:	English
ACCESSION:	WOS:000208892400045
DOI:	10.1200/jco.2012.30.5_suppl.43
PROVIDER:	wos
Notes:	Meeting Abstract: 43 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/152014